Interestingly, we found that composite score for ERRβ IHC staining was significantly high in ER + ve breast cancer patients (n = 6) than in patients with ER-ve receptor status (n = 6) suggesting that ERRβ expression might be controlled by ERα (Fig. 2a, b). The gene discussed is ESR1; the disease is breast carcinoma.